The outlook for dementia care is changing fast. UC experts explain what that means for patients and families, and what it ...

A new study reveals that obesity accelerated Alzheimer's blood biomarkers by 95% over five years, highlighting a strong ...

Major Alzheimer’s breakthroughs in 2025 include new FDA-approved blood tests, at-home treatments, and lifestyle research showing cognitive benefits for older adults.

Research shows the p-tau217 blood test can indicate very high risk of Alzheimer's disease before symptoms begin, offering ...

New research published in the journal eNeuro examined whether eliminating a protein that is elevated in the brains of those ...

GLP-1 drugs, which include Ozempic and Wegovy, have become one of the most closely watched experimental approaches for ...

High-sensitivity C-reactive protein (CRP) decreased significantly in the semaglutide group, with estimated treatment ratios ...

New findings show that removing Centaurin-α1, a protein elevated in Alzheimer’s disease, significantly reduces inflammation, plaque buildup, and cognitive deficits in a well-established mouse model.

A deep analysis of semaglutide’s phase 3 AD trials shows no cognitive or functional benefit despite biomarker gains, yet ...

New research shows obesity speeds up Alzheimer’s biomarkers by up to 95%, detectable through early blood tests.

Researchers have conducted the first study evaluating the impact of obesity on Alzheimer's disease blood biomarkers (BBMs).

Alzheimer's disease is one of the main causes of dementia. Currently, there are a limited number of treatments available, ...